The news is directly about Alnylam Pharmaceuticals and its rating by Cantor Fitzgerald. The reiteration of a Neutral rating and maintenance of the $190 price target suggests that the analyst sees no significant changes in the company's outlook in the short term. This is likely to have a neutral impact on the stock's price.